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EIE: extracted ion electropherogram. 
FAP-I: familial amyloidotic polyneuropathy type I. 
HAc: acetic acid. 
 
 
HFor: formic acid. 
IA: immunoaffinity. 
MB: magnetic bead. 
MeOH: methanol. 
Mr: relative molecular mass. 
MWCO: molecular weight cut-off. 
ProA: protein A. 
PTM: post-translational modification. 
TIE: total ion electropherogram. 
tm: migration time. 
TTR: transthyretin. 
UV: ultraviolet spectrophotometry. 
 









In this paper, an on-line immunoaffinity solid-phase extraction capillary electrophoresis 
mass spectrometry (IA-SPE-CE-MS) method using magnetic beads (MBs) is described 
for the analysis of serum transthyretin (TTR), which is a protein related to different 
types of amyloidosis. First, purification of TTR from serum was investigated by off-line 
immunoprecipitation and CE-MS. The suitability of three Protein A (ProA) MBs 
(Protein A Ultrarapid AgaroseTM (UAPA), Dynabeads® Protein A (DyPA) and SiMAG-
Protein A (SiPA)) and AffiAmino Ultrarapid AgaroseTM (UAAF) MBs to prepare an IA 
sorbent with a polyclonal antibody (Ab) against TTR, was studied. In all cases results 
were repeatable and it was possible the identification and the quantitation of the relative 
abundance of the 6 most abundant TTR proteoforms. Although recoveries were the best 
with UAPA MBs, UAAF MBs were preferred for on-line immunopurification because 
Ab was not eluted from the MBs. Under the optimised conditions with standards in IA-
SPE-CE-MS, microcartridge lifetime (>20 analyses/day) and repeatability (2.9 and 4.3 
% RSD for migration times and peak areas) were good, the method was linear between 
5- 25 µg·mL-1 and limit of detection (LOD) was around 1 µg·mL-1 (25 times lower than 
by CE-MS, 25 µg·mL-1). A simple off-line sample pretreatment based on precipitation 
of the most abundant proteins with 5% (v/v) of phenol was necessary to clean-up serum 
samples. The potential of the on-line method to screen for familial amyloidotic 
polyneuropathy type I (FAP-I), which is the most common hereditary systemic 










Capillary electrophoresis mass spectrometry (CE-MS) is nowadays a mature technique 
with many interesting application areas, especially those that require the highly efficient 
separation and characterisation of biomolecules, including peptides, protein isoforms, 
glycoforms, glycopeptides, protein-protein or drug-protein complexes [1–7]. However, 
the low concentration sensitivity for most analytes is very often a limitation that hinders 
a more widespread application [8–12]. The use of more selective and sensitive mass 
spectrometers is often not enough to decrease the limit of detection (LOD). Therefore, 
CE-MS has been often combined with different electrophoretic and chromatographic 
techniques for the on-line preconcentration of the target analytes after the injection of a 
large volume of sample, such as sample stacking, isotachophoresis or on-line solid 
phase extraction (SPE-CE) [10–14].  
 
In SPE-CE, a microcartridge with an appropriate sorbent is inserted near the inlet of the 
separation capillary to preconcentrate and clean up the target analytes from a large 
volume of sample. As extraction occurs immediately before the electrophoretic 
separation without human handling, many pioneering authors in the field referred the 
coupling as “on-line” since the late 80s [8,9,15]. However, other authors have preferred 
the term “in-line” because the microcartridge is fully integrated with the separation 
capillary [10–12]. Both terms are actually coexisting in the literature, something that 
has generated some controversy [16,17]. SPE-CE-MS has been extensively explored 
using the silica or polymeric sorbents typically used in off-line SPE (e.g. C18) [11–
14,16,17], because of the versatility, the large active surface area, the compatibility with 





reasonable price. However, the limited selectivity of such sorbents hinders very often 
the analysis of complex samples, such as biological fluids, even with MS detection 
[14,16,17]. Immunoaffinity (IA) sorbents are an interesting alternative with improved 
selectivity, which may provide excellent extraction efficiency if the immunoreactivity 
and orientation of the antibody (Ab) and the active surface area are optimum and non-
specific adsorption is minimized [8,9,18,19]. However, in addition to the limited 
commercial availability of IA sorbents with the most appropriate features for IA-SPE-
CE-MS, it is a challenge to make compatible IA sorbent stability, on-line 
immunoextraction and MS detection [18–22]. It is well-known that extreme ionic 
strength, high temperature and acidic or alkaline conditions may cause antibody 
denaturation. Furthermore, with on-line MS detection, solutions must be volatile to 
prevent salt build-up in the mass spectrometer. This is the reason why only a few 
authors have demonstrated IA-SPE-CE-MS with lab-made porous silica or agarose IA 
sorbents for the analysis of small peptides and proteins [18–22].  
 
In the last decade, many different magnetic beads (MBs) have become commercially 
available with a wide range of surface chemistries to easily and reproducibly couple 
many types of microorganisms, cells or biological molecules, including Ab [23–25]. 
The robustness and versatility of the commercial MBs and the simplicity of operation 
are rapidly expanding the application areas, including IA-SPE-CE [26–33]. Since the 
pioneering work of Rashkovetsky et al [26], several authors have described the use of 
IA-MBs in capillary or microchip format with ultraviolet (UV) [27,31], fluorescence 
[26,28–30] or MALDI-MS [32,33] detection, but not yet with fully on-line ESI-MS 
detection. One of the great advantages of MBs in IA-SPE-CE is that facilitate the 





because permanent magnets or electromagnets can be used to trap or move the particles. 
Between the disadvantages, it is worth mentioning that in general many commercial 
MBs are not porous, which is a limitation for the active surface area, especially when 
the amount of sorbent is small such as in capillaries and microchannels. Furthermore, 
little is known about the influence of the biological molecules on the formation and 
retention of MB plugs in a capillary or a microdevice [34] or about the influence of the 
external magnetic field in the extraction procedures [35]. 
  
In this paper is described, for the first time to the best of our knowledge, an IA-SPE-
CE-MS method using MBs. The method is applied to the analysis of serum TTR. TTR 
is a homotetramer composed of four identical monomers (MO) (relative molecular mass 
(Mr)14,000) with different proteoforms (isoforms and post-translational modifications 
(PTMs)) [36–41]. TTR is known to misfold and aggregate as stable insoluble fibrils due 
to mutations and conformational changes, causing different neurodegenerative diseases 
known as amyloidosis [42,43]. Some of the 100 point mutations known in the TTR-
gene are related to different types of hereditary TTR amyloidosis, such as  familial 
amyloidotic polyneuropathy type I (FAP-I) [36,37,39,44]. FAP-I is associated with a 
TTR variant that presents a single amino acid substitution of valine for methionine at 
position 30 (Met 30). First, analysis of TTR from serum was investigated by off-line 
immunoprecipitation and CE-MS with different MBs derivatized with a polyclonal Ab. 
Later, on-line IA-SPE-CE-MS was optimised and the potential to screen rapidly and 
reliably for FAP-I was demonstrated analysing serum samples from healthy controls 





2. Materials and methods 
 
2.1. Chemicals and reagents 
 
All the chemicals used in the preparation of background electrolytes (BGEs) and 
solutions were of analytical reagent grade or better. Propan-2-ol (≥99.9%), methanol 
(≥99.9%), formic acid (HFor) (99.0%), acetic acid (HAc) (glacial), ammonia (25%), 
hydrochloric acid (25%), sodium hydrogenphosphate (≥99.0%), sodium chloride 
(≥99.5%), sodium hydroxide (≥99.0%), phenol (≥99.5%), potassium 
dihydrogenphosphate (≥99.0%), potassium chloride (99.0%), glycine (Gly) (99.7%) and 
TTR (≥95.0%) were purchased from Merck (Darmstadt, Germany). 
Tris(hydroxymethyl)aminomethane (Tris) (≥99.5%) was purchased from Baker 
(Deventer, Holland). Water (LC-MS grade) and acetonitrile (LC-MS grade) for sample 
pretratment and CE-MS experiments, and ammonium acetate (NH4Ac) (≥99.9%) were 
supplied by Sigma (St. Louis, MO, USA). In the rest of experiments, water with a 
conductivity value lower than 0.05 µS·cm-1 was obtained using a Milli-Q water 
purification system (Millipore, Molsheim, France). 
 
Rabbit antihuman TTR polyclonal Ab was purchased from Dako (Glostrup, Denmark). 
The different MBs were provided by different manufacturers. Superparamagnetic 
agarose beads Protein A Ultrarapid AgaroseTM (UAPA) and AffiAmino Ultrarapid 
AgaroseTM (UAAF) of 45-165 µm diameter were supplied by Lab on a Bead (Uppsala, 
Sweden). Superparamagnetic silica beads Dynabeads® Protein A (DyPA) of 2.8 µm 
diameter were purchased from Life Technologies (Carlsbad, CA, USA). 





provided by Chemicell GmbH (Berlin, Germany). The crosslinker BS3 
(bis(sulfosuccinimidyl)suberate) was purchased from Pierce Biotechnology (Rockford, 
IL, EUA). 
 
2.2. Electrolyte solutions, sheath liquid, protein standards and serum samples. 
 
The BGE for CE-MS separation contained 1 M HAc (pH 2.3) or 10 mM NH4Ac, 
adjusted to pH 7.0 with ammonia, for off-line immunoprecipitation or on-line IA-SPE-
CE, respectively. Both BGEs were passed through a 0.22 µm nylon filter (MSI, 
Westboro, MA, USA). The sheath liquid solution consisted of a mixture of 60:40 (v/v) 
propan-2-ol:water with 0.05% or 0.25% (v/v) of HFor for the acidic or the neutral 
BGEs, respectively. With the neutral BGE, the percentage of HFor in the sheath liquid 
was higher for optimum detection sensitivity of TTR [45]. The sheath liquid and the 
BGEs were degassed for 10 min by sonication before use.  
 
An aqueous standard solution (1,000 µg·mL-1) of TTR was prepared and stored in a 
freezer at -20ºC when not in use. Excipients of low Mr were removed from the sample 
by passage through 10,000 Mr cut-off (MWCO) cellulose acetate filters (Amicon Ultra-
0.5, Millipore). The sample was centrifuged at 25ºC for 10 min at 11,000 x g and the 
residue was washed three times for 10 min in the same way, with an appropriate volume 
of acidic BGE or phosphate buffered saline (PBS) (0.011 M sodium 
hydrogenphosphate, 0.0015 M potassium dihydrogenphospate, 0.14 M sodium chloride, 
0.0027 M potassium chloride, pH 7.2) for off-line immunoprecipitation or IA-SPE-CE, 





and spinning once more at a reduced centrifugal force (2 min at 300 x g). Sufficient 
acidic BGE or PBS was added to adjust the concentration of TTR to 1,000 µg·mL-1. 
 
Human blood samples from a healthy control and a symptomatic FAP-I patient were 
kindly supplied by the Hospital Universitari de Bellvitge (HUB, Hospitalet de 
Llobregat, Spain). The assay was approved by the Ethics Committee of the HUB and 
written informed consent was obtained from all participants in the study. Serum was 
prepared as described in our previous work [45]. Serum aliquots were stored in a freezer 
at -20ºC when not in use. 
 
2.3. Apparatus and procedures 
 
pH measurements were made with a Crison 2002 potentiometer and a Crison electrode 
52-03 (Crison Instruments, Barcelona, Spain). Centrifugal filtration was carried out in a 
cooled Rotanta 460 centrifuge (Hettich Zentrifugen, Tuttlingen, Germany) for 
centrifugation at controlled temperature (4 or 25ºC). Agitation was performed with a 
Vortex Genius 3 (Ika®, Staufen, Germany). Neodymium block magnets (7 x 6 x 1.2 
mm, N50) were supplied by Supermagnete (Gottmadingen, Germany). A neodymium 
cube magnet (12 mm, N48) was supplied by Lab on a Bead.  
 
2.3.1. Off-line immunoprecipitation with MBs and CE-MS  
 
Serum samples were immunopurified using the anti-TTR Ab coupled to the different 
MBs following the manufacturer’s instructions. First, the solvent of the commercial Ab 





section 2.2 for the TTR standard). After that, 50 µL of MBs were vortexed and the 
supernatant was removed using a cube magnet to sediment the particles (magnetic 
separation). The MBs were washed with 100 µL of PBS twice and resuspended in 50 
µL of PBS. 50 µL of Ab in PBS solution (2,400 µg·mL-1) were then added to the MBs 
suspension. The mixture was moderately shaken for 40 min at room temperature. The 
supernatant was removed by magnetic separation and the MBs were subsequently 
washed three times with 100 µL of PBS. Only for crosslinking of UAPA MBs a 100 
mM BS3 in PBS stock solution was prepared immediately before use. A volume of 250 
µL of a 30 mM BS3 solution prepared from the stock solution was added to the MBs 
suspension in PBS. The mixture was moderately shaken for 30 min at room 
temperature. Then, 13 µL of a 1 M Tris (pH 7.5) solution were added and the mixture 
was shaken for 15 min. The crosslinked UAPA MBs were washed and stored in PBS as 
indicated before.  
 
For off-line immunoprecipitation of TTR, 50 (DyPA) or 75 µL (UAPA, UAAF and 
SiPA) of serum sample were added to the MBs, depending on the binding capacity 
declared by the manufacturer (0.24, >3, >0.5 and 5 mg Ab/mL MB, respectively), and 
the mixture was incubated for 20 min at room temperature with gentle orbital shaking. 
Again, the supernatant was removed and the MBs were then washed three times with 
200 µL of PBS. Finally, in order to elute TTR, 50 µL of 50 mM glycine (adjusted to pH 
2.8 with HCl) were added and the mixture was incubated for 5 min at room temperature 
with orbital shaking. The supernatant containing the eluted TTR was collected and 
transferred into a clean microcentrifuge vial. Non volatile components of low Mr were 
removed by centrifugal filtration (see section 2.2) and solvent was changed to the acidic 






Fused silica capillaries were supplied by Polymicro Technologies (Phoenix, AZ, EUA). 
All CE-MS experiments were performed in an HP3D CE system coupled with an 
orthogonal G1603A sheath-flow interface to a 6220 oa-TOF LC/MS spectrometer 
(Agilent Technologies, Waldbronn, Germany). The sheath liquid was delivered at a 
flow rate of 3.3 µL·min-1 by a KD Scientific 100 series infusion pump (Holliston, MA, 
USA). ChemStation and MassHunter softwares (Agilent Technologies) were used for 
CE and TOF mass spectrometer control, data acquisition, integration and m/z mass 
spectra deconvolution. The TOF mass spectrometer was operated under optimum 
conditions in positive mode using the following parameters: capillary voltage 4,000 V, 
drying gas temperature 300ºC, drying gas flow rate 4 L·min-1, nebulizer gas 7 psig, 
fragmentor voltage 325 V, skimmer voltage 80 V, OCT 1 RF Vpp voltage 300 V. Data 
were collected in profile at 1 spectrum/s between 100 and 3,200 m/z, with the mass 
range set to high resolution mode (4 GHz). 
 
Separations were performed at 25°C in a 72 cm long (LT) × 75 µm id × 365 µm od 
capillary. All capillary rinses were performed at high pressure (930 mbar). New 
capillaries were flushed with 1 M NaOH (15 min), water (15 min) and BGE (30 min). 
The system was finally equilibrated by applying the 25 kV separation voltage (normal 
polarity, cathode in the outlet) for 15 min. Between workdays, the capillary was 
conditioned by rising successively with 0.1 M NaOH (5 min), water (10 min) and BGE 
(15 min). Both activation and conditioning procedures were performed off-line to avoid 
the unnecessary entrance of NaOH into the MS system. Samples were 





conditioned flushing at 930 mbar for 2 min with BGE, 1 min with H2O and 1 min with 
BGE.  
 
2.3.2. On-line IA-SPE-CE-UV and IA-SPE-CE-MS 
 
 
These experiments were performed only with UAPA and UAAF MBs, which were 
derivatized with the Ab as explained in section 2.3.1. Each prepared IA-MB batch was 
stored in the fridge when not in use.  
 
Construction of the IA microcartridge or analyte concentrator could be carried out as 
described elsewhere taking advantage of agarose MBs size [13,17] or their magnetic 
properties. In the first design, which is depicted in Figure 1-A, the microcartridge (0.9 
cm LT × 250 µm id × 365 µm od capillary) was inserted using two plastic sleeves at 7.5 
cm from the inlet of a previously conditioned separation capillary (75 µm id × 365 µm 
od x LT 57 or 72 cm, with UV and MS detection, respectively). It was filled before 
connection by vacuum, and the IA-MBs were retained mostly due to particle size (>75 
μm id capillary) hence neither frits nor magnet were required [17]. In the second design, 
the 0.9 cm microcartridge was similarly constructed in one of the ends of an 8.5 cm LT 
× 250 µm id × 365 µm capillary fragment (Figure 1-B). This capillary was connected 
with a plastic sleeve to the conditioned separation capillary (see dimensions above). A 
12 mm cubic magnet helped during vacuum filling from the outlet end, since the 
particles were strongly retained and packed when they entered the strongly magnetised 
section in the end of the 250 µm id capillary. After this, the particles outside the 0.9 cm 
magnetised section were easily removed by applying vacuum in the opposite direction. 





placing a smaller block magnet (7 x 6 x 1.2 mm) in the cartridge cassette to maintain the 
particles in the microcartridge. As can be observed in Figure 1-B, the magnet did not 
need to cover the whole microcartridge body.  
 
In all these experiments, the neutral BGE was used to avoid extreme pH that would 
cause Ab denaturation and protein elution. Capillaries were first conditioned flushing at 
930 mbar for 2 min with BGE. TTR standards in PBS and serum samples were 
hydrodynamically introduced at 930 mbar for 10 min (75 and 60 µL with UV and MS 
detection, respectively, using the Hagen-Poiseuille equation [46]). A final rinse with 
BGE (2 min, 930 mbar) eliminated non-retained molecules and equilibrated the 
capillary before the electrophoretic separation. Under optimised conditions, an eluent of 
100 mM NH4OH (pH 11.2) was injected at 50 mbar for 10 s (70 and 50 nL with UV and 
MS detection, respectively [46]). For a rapid and quantitative protein elution, a 25 mbar 
pressure was applied for 150 s (i.e. BGE was introduced) before beginning the 
separation in order to guarantee that the elution plug passed through the IA-MBs [14]. 
With MS detection, all these steps were performed by switching off the nebulizer gas 
and the ESI capillary voltage to prevent non-volatile and contaminants entrance into the 
MS. Then, both were switched on and separation was carried out at 25°C and +25 kV 
(normal polarity). Between runs, to avoid carry-over the capillary was rinsed with 100 
mM NH4Ac (pH 7.0) and water (2 min at 930 mbar both).  
 
A simple off-line sample pretreatment was required to analyse TTR in serum samples to 
prevent microcartridge saturation and capillary inner surface damage due mostly to the 
presence of other high-abundance proteins, such as albumin. A method for the isolation 





8 mg of NaCl were added to 100 µL of human serum and then dropwise 100 µL of 5% 
(v/v) phenol. Most of the proteins precipitated and TTR remained in solution, which lost 
the yellowish colour of the serum. Under the optimised conditions, the supernatant was 
collected after centrifugation for 10 min at 11000 x g and then diluted 1:1 (v/v) with 
PBS before analysis.  
 
2.3.3. Quality parameters  
 
All quality parameters with MS detection were calculated from data obtained by 
measuring peak area and migration time (tm) from the extracted ion electropherogram 
(EIE) of TTR proteoforms (considering the m/z of the most abundant molecular ions, 
i.e. ions with charges +16, +15, +14, +13). Repeatability was evaluated as the relative 
standard deviation (%RSD) of peak areas and tm. Linearity range was established by 
analysing standard solutions of TTR at concentrations between 1 and 50 µg·mL-1. An 
estimation of the LODs was obtained by analysing low-concentration standard solutions 
of TTR (close to the LOD level, as determined from the approach based on S/N=3). The 
lifetime of the microcartridges was evaluated by repeatedly analysing a standard 
solution of TTR at a concentration of 10 µg·mL-1 and pretreated human serum samples.  
 
3. Results and discussion 
 
3.1. Off-line immunoprecipitation with MBs and CE-MS  
 
The performance for TTR purification of all the MBs was investigated first by off-line 





ProA MBs with different particle size and binding capacity from three manufacturers 
(UAPA, DyPA and SiPA) because Protein A strongly interacts with the Fc portion of 
the Ab (IgG) allowing an optimum Ab orientation. However, as there is no covalent 
bond between the Ab and the MBs, the elution conditions are typically harsh enough to 
elute the Ab together with the antigenic protein (e.g. 50 mM Gly-HCl (pH 2.8) in our 
case). As an alternative to the ProA MBs we also investigated UAAF MBs, which are 
functionalized with amino-reactive groups and covalently bound to the Ab without a 
preferred orientation. TTR was purified from serum samples by off-line 
immunoprecipitation and analysed by CE-MS. The relative recoveries (referred to the 
highest one) and repeatabilities (as %RSD, n=6) were calculated under the different 
conditions taking into account the peak area of the most abundant TTR proteoform 
(TTR-Cys, see Table 1). These values were 100% (2.3%), 80% (5.0%), 16% (4.3%) for 
UAPA, SiPA and DyPA, respectively and 52% (4.6%) for UAAF. The best recoveries 
were obtained with UAPA and SiPA MBs which presented the highest binding capacity 
(>3 and 5 mg Ab/mL MB, respectively), but in both cases the Ab was eluted with TTR 
and could be detected by CE-MS (see the electropherogram and mass spectra for UAPA 
in Figure 2-A). In contrast, recoveries were slightly lower with UAAF MBs but the 
antibody was not detected (Figure 2-B). In all cases, results were repeatable and the 
same TTR proteoforms were detected with similar relative abundances. As an example, 
Figure 2-B shows the mass spectrum (ii) and the deconvoluted mass spectrum (iii), 
using UAAF MBs. Table 1 shows information about the detected proteoforms for 
monomeric (MO) TTR, the relative error (Er) for experimental Mr, the relative 
abundance (%A) and its %RSD. Mass accuracy was good (Er < 60 ppm), as well as %A 
repeatability (%RSD<5.7%). The detected proteoforms agreed with those reported by 





at low concentration. This is the case, for example of TTR-Glutathione that presented a 
%A of 21% compared to TTR-Cys, which was the most abundant proteoform. 
However, it is important to note that mass accuracy was not enough to differentiate 
between the TTR-Phosphorylated and TTR-Sulfonated (N=3, Table 1) or between TTR-
Dehydroxylated or TTR-Sulfinic (N=4, Table 1) proteoforms, which were neither 
separated by electrophoresis.  In these cases, reliability of the identification would 
improve running -MS and -MS/MS experiments using mass spectrometers with 
improved mass accuracy and resolution.  
 
Although, reliable and repeatable results were obtained, the off-line method was time-
consuming, it could not be automated and it was relatively expensive considering the 
amount of IA-MBs consumed in each analysis and that they were not reused. As an 
alternative to solve these issues, we investigated the on-line immunopurification. 
 
3.2. On line IA-SPE-CE-UV and IA-SPE-CE-MS 
 
As we mentioned before, in all these experiments a neutral BGE was used because the 
acidic BGE would cause Ab denaturation and protein elution during capillary 
conditioning [18–22]. In our previous work [45], we showed that this neutral BGE 
allowed detecting by CE-MS the same TTR proteoforms than the acidic BGE, but 
sensitivity was lower. For ease of comparison later with on-line IA-SPE-CE-MS, Figure 
3-A shows the EIE , the mass spectrum and the deconvoluted mass spectrum for a 50 
µg·mL-1 TTR standard using the neutral BGE by CE-MS. As can be seen in the 
deconvoluted mass spectrum (Figure 3-A (iii)), only five of the six TTR proteoforms 










Some preliminary studies that were performed with UAPA and UAAF MBs and UV 
detection demonstrated that TTR standards needed to be dissolved in PBS, because TTR 
was not retained when dissolved in water or neutral BGE. PBS is a solution with a 
similar osmolarity and ion concentration to the human body fluids and probably 
benefited the interaction between TTR and the Ab. The performance of the two 
microcartridge designs depicted in Figure 1-A and –B was similar. However, the second 
one (Figure 1-B) had several remarkable advantages, such as the presence of only one 
capillary connection and the simplicity to fill with MBs. These features increased the 
robustness and reusability of the system, because facilitated vacuum packing and 
particle replacement by removing the block magnet and applying pressure. 
 
With regard to the volatile eluent, based on our experience, two acidic, 100 mM HAc 
(pH 2.9) and 50mM:50 mM HAc:HFor (pH 2.3),  and a basic eluent, 100 mM NH4OH  
(pH 11.2), were tested. When using UAPA MBs, TTR was eluted with all three eluents. 
However, repeatability was poor and TTR recovery diminished after several injections 
due to the gradual elution of the Ab. Crosslinking of UAPA MBs with BS3 was studied 
in order to covalently bound the Ab to the ProA to avoid Ab elution. Nevertheless, 
crosslinked UAPA MBs did not allow detecting TTR by CE-MS, probably because 
antigen-binding site was modified and the Ab lost its function. The performance of the 





were detected and the sorbent was irreversibly damaged for subsequent analyses with 
the basic eluent (repeatability was low, analysis time increased and TTR peak area 
decreased).  When using UAAF MBs and the basic eluent, the Ab was not eluted and 
results for TTR were good. A higher amount than 100 mM of NH4OH in the eluent was 
not tested to prevent Ab denaturation and expand the sorbent lifetime. The UV 
electropherograms of on-line preconcentration of TTR standards in PBS showed two 
peaks, the first related to the solvent and the second to TTR (Figure 4-A). In order to 
avoid carry-over, the postconditioning washing time with 100 mM NH4Ac (pH 7.0) and 
water needed to be increased until 2 minutes.  
 
Sample loading time was studied loading a 10 µg·mL-1 TTR standard solution at 930 
mbar for 5, 10 and 15 min. As can be seen in Figure 4-B, a loading time of 10 min was 
selected for the rest of experiments because peak area of the eluted TTR was maximum. 
At 15 min protein breakthrough during sample loading caused a decrease of peak area. 
Under the optimised conditions, consecutives analyses of TTR standards were 
repeatable in terms of tm and peak area (%RSD (n=3) 4.3 and 4.6%, respectively, for a 
10 µg·mL-1 TTR standard). LOD was around 2 µg·mL-1 and the method was linear 




The optimised method with UV detection was evaluated with MS detection, but needed 
a small adjustment because TTR was sometimes eluted as a double peak. Several 
alternatives were explored to improve TTR elution. First, organic modifiers were added 





detected. Next, a larger basic elution plug of 40 s at 50 mbar was tested but TTR peak 
broadened. Finally, the solution to reproducibly elute TTR as a single peak was to apply 
a 25 mbar pressure for 150 s after the elution plug injection and before beginning the 
separation in order to guarantee that the elution plug passed through the IA-MBs [14]. 
Figure 3-B shows the EIE, the mass spectrum and the deconvoluted mass spectrum for a 
25 µg·mL-1 TTR standard, a concentration close to the LOD by CE-MS with the neutral 
BGE. Compared to the CE-MS electropherogram of a 50 µg·mL-1 TTR standard shown 
in Figure 3-A preconcentration was significant. However, taking into account the 
volume of sample loaded on-line (60 µL) recoveries were much lower than previously 
with the off-line method, probably due to the limited amount of sorbent, smaller Ab-
TTR ratio and the shorter interaction time. Figure 3-B shows that at 25 µg·mL-1 with the 
on-line method three extra proteoforms were detected (TTR-glutathione, TTR-CysGly 
and TTR-CysGlu). As shown in Table 2, only at a concentration of 1000 µg·mL-1 of 
TTR the number of detected proteoforms by CE-MS was similar than by IA-SPE-CE-
MS, as well as the mass accuracy (Er) and repeatability (%RSD %A). The increase of 
the %A for the different proteoforms in IA-SPE-CE-MS, which was referred to TTR-
Cys, could be related to the lower recovery of TTR-Cys compared to the rest of 
proteoforms. Under the optimised conditions, results were repeatable in terms of tm and 
peak area (TTR-Cys %RSD (n=3) 2.9 and 4.3%, respectively), LOD was around 1 
µg·mL1 (25 times lower than by CE-MS, ≈25 µg·mL-1) and the method was linear 
(r2>0.99) between 5 and 25 µg·mL-1. The lifetime of the microcartridges was superior to 
20 analyses during the same day. After that, peak areas decreased until no detecting 
TTR due to sorbent deterioration. Something similar happened, even after a smaller 
number of analyses, if capillaries were stored overnight in the fridge or at room 






The on-line method optimised with standards was applied to the analysis of TTR in 
serum samples. Loading of serum samples without any pretreatment was not possible 
because of current instability and breakage. Several off-line sample pretreatments were 
studied in order to prevent microcartridge saturation and capillary inner surface damage 
due to the loading of salts and other high-abundance proteins, such as albumin. Serum 
filtration (0.22 µm pore) and dilution with water or PBS (1:1 or 1:10 (v/v)) or protein 
precipitation with acetonitrile, were not useful. Finally we applied a very simple method 
of protein precipitation with 5% (v/v) of phenol  that allowed excellent TTR recoveries 
(around 90% from comparison of CE-MS analysis of a serum sample pretreated and 
desalted with 10,000 MWCO filters and a 250 µg·mL-1 TTR standard) [47,48]. Figures 
5 A-C show the EIEs of the supernatant collected for a serum sample from a healthy 
control diluted 1:8, 1:4 and 1:1 (v/v) with PBS, respectively. As can be observed, TTR 
was detected at around 22 minutes and the largest peak was obtained in the less diluted 
sample. Furthermore, a small amount of albumin was still detected between 8 and 14 
minutes in all cases. In this regard, the increase in tm of TTR with serum samples 
compared to standards (Figure 3-B) was probably due to the modification of the inner 
wall of the separation capillary induced during loading by the remaining proteins that 
were not retained by the Ab. This modification was permanent, because TTR was also 
detected at this tm when a standard was analysed after a serum sample. Anyway, results 
were repeatable in terms of tm and peak area (TTR-Cys %RSD (n=3) were 4.7 and 
3.2%, respectively, for a 1:1 (v/v) serum sample). In diluted 1:4 and 1:8 (v/v) samples 
only three of the main TTR proteoforms were detected (data not shown). In contrast, the 
five most abundant TTR proteoforms were detected in the 1:1 (v/v) sample (Figure 5-





B). For the 1:1 (v/v) dilution, the lifetime of the microcartridges was lower than for 
TTR standard solutions (>10 vs >20 analyses during the same day) due to the higher 
sample matrix complexity The on-line method was finally applied to the analysis of a 
serum sample from an FAP-I patient. Figure 5-D shows the EIE and the deconvoluted 
mass spectrum of TTR in the FAP-I patient serum sample. Table 3-B shows the 
information about the detected proteoforms, which are very similar to those obtained for 
the healthy control. As can be observed, all the main normal TTR proteoforms were 
detected as well as the main mutant proteoforms (TTR-Cys (Met30) and Free-TTR 
(Met30)). However, the mass spectrometer mass accuracy was not enough to 
differentiate between mutant free-TTR (Met30), TTR-Dehydroxylated or TTR-Sulfinic 
(N=4, Table 3). Therefore, although the %A corresponding to these three proteoforms in 
the FAP-I patient was higher than the summed contribution of the two normal 
proteoforms in the healthy control (table 3), only detection of the TTR-Cys (Met30) 
proteoform would unambiguously confirm the TTR amyloidosis.  
 
4. Concluding remarks 
 
We have developed a method for purification, separation and characterization of TTR 
from serum samples by off-line immunoprecipitation with UAPA MBs and CE-MS 
with an acidic BGE. In order to minimize sample manipulation, increase analysis 
throughput and reduce consumption of IA-MBs, while maintaining the reproducibility 
and reliability of the method, we have also developed a novel on-line IA-SPE-CE-MS 
method.  Although recoveries were the best with UAPA MBs in the off-line method, 
UAAF MBs were preferred for the on-line immunopurification because Ab was not 





and peak areas were repeatable (%RSD<5%), microcartridge lifetime was good (>10 
(serum samples) and >20 (standards) analyses/day), the method was linear between 5 
and 25 µg·mL-1 and LOD was 25 times lower (1 µg·mL-1) than in CE-MS (25 µg·mL-1). 
Finally, the potential of the on-line method to screen serum samples for FAP-I was 
confirmed after developing a simple off-line clean-up pretreatment based on protein 
precipitation with 5% (v/v) of phenol. In view of our experience and the results 
achieved, MBs offer a powerful alternative to expand the applicability of on-line IA-
SPE-CE and an excellent opportunity to engage unskilled operators interested in IA or 
other type of sorbents. For example, we are currently exploring if the magnetic 
microcartridge design (Figure 1-B) can be applied to prepare frits with chemically inert 
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Figure 1. Representations of the microcartridge designs A) UAPA or UAAF MBs are 
trapped in a microcartridge body of 250 µm id due to their particle size and B) UAPA or 
UAAF MBs are retained in one of the ends of a piece of 250 µm id capillary and a 
magnet prevents the shift and loss of the MBs. (The first design could not be applied 
with SyPA and DyPA MBs because both are very small. Similarly, in the second case 
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Figure 2. CE-MS using 1 M HAc as BGE after the off-line immunoprecipitation of a 
healthy control serum sample using A) UAPA and B) UAAF MBs. (i) Total ion 
electropherogram (TIE), (ii) mass spectrum and (iii) deconvoluted mass spectrum. (Ab: 
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i) Extracted ion electropherogram (EIE)












Figure 3. A) CE-MS for a 50 µg·mL-1 TTR standard using 10 mM NH4Ac (pH 7.0) as 
BGE. B) IA-SPE-CE-MS for a 25 µg·mL-1 TTR standard using UAAF MBs. (i) Total 
ion electropherogram (TIE), (ii) mass spectrum and (iii) deconvoluted mass spectrum.  
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Figure 4. A) IA-SPE-CE-UV for a 10 µg·mL-1 TTR standard using UAAF MBs and 
100 mM NH4OH as eluent. B) Study of sample loading time at 930 mbar on the peak 










































































































































































































































Figure 5. IA-SPE-CE-MS for serum samples pretreated with 5% (v/v) phenol solution. 
The supernatants of the healthy controls and the FAP-I patient samples were diluted 
with PBS A) 1:8, B) 1:4 C) 1:1 and D) 1:1 (v/v). In C) and D) are shown the TTR 





Table 1. Theoretical and deconvoluted average Mr and relative abundance for the detected TTR proteoforms of a healthy control serum sample 
by off-line immunoprecipitation with UAAF MBs and CE-MS (BGE: 1M HAc, pH 2.3). 
  
 
Off-line immunoprecipitation and CE-MS 
N 




Deconvoluted Average Mr 
%Ab) (%RSD) 
Experimental Era) (ppm) 
1. TTR-Cys 13880.4022 13880.9073 36 100 (3.4) 
2. Free-TTR 13761.2640 13761.8857 45 64 (2.0) 




 or TTR-Sulfonated 13841.3283 10 
4. TTR-Dehydroxylated or 
TTR-Sulfinic 
13793.2628 13794.0858 60 33 (5.7) 
5.  (10) C-G 13715.1713 13715.4153 18 33 (4.8) 
6. TTR-Glutathione 14066.9600 14067.8108 60 21 (4.7) 
 
a) Relative error (Er) was calculated in ppm as: |Mr exp – Mr theo|/Mr theo × 10
6 (exp = experimental and theo = theoretical). 





Table 2. Theoretical and deconvoluted average Mr and relative abundance for the detected proteoforms of a 1000 µg·mL
-1 TTR standard by CE-
MS and 25 µg·mL-1 TTR standard by IA-SPE-CE-MS with UAAF MBs (BGE: 10 mM NH4Ac, pH 7.0). 
   A) CE-MS B) IA-SPE-CE-MS 
N 




Deconvoluted Average Mr 
%Ab) 
(%RSD)  
Deconvoluted Average Mr 
%Ab) 
(%RSD) Experimental Era) (ppm) Experimental Era) (ppm) 
1. TTR-Cys 13880.4022 13880.9192 37 100 (1.6) 13881.0508 47 100 (4.3) 
2. Free-TTR 13761.2640 13762.4781 53 41 (0.5) 13761.7772 37 62 (0.9) 
3. TTR-Phosphorylated    13841.2439 
13841.0308 
15 
35 (3.0) 13841.0479 
41 
60 (2.6) 
 or TTR-Sulfonated 13841.3283 21 43 
4. TTR-Dehydroxylated   
or TTR-Sulfinic 
13793.2628 13793.8311 41 37 (2.9) 13793.6805 30 53 (1.9) 
5.  (10) C-G  13715.1713 13715.8205 47 35 (5.9) 13715.5892 30 62 (4.0) 
6. TTR-Glutathione 14066.9600 14067.3258 26 20 (5.4) 14067.2015 17 35 (1.7) 
7. TTR-CysGly 13937.4541 13938.2189 55 32 (4.9) 13937.7082 18 48 (2.2) 
8. TTR-CysGlu 14009.5177 Not detected - - 14009.3011 15 27 (5.3) 
 
a) Relative error (Er) was calculated in ppm as: |Mr exp – Mr theo|/Mr theo × 10
6 (exp = experimental and theo = theoretical). 





Table 3. Theoretical and deconvoluted average Mr and relative abundance for the detected TTR proteoforms in serum samples pretreated with 
5% (v/v) phenol solution (dilution 1:1 (v/v)) by IA-SPE-CE-MS (BGE: 10 mM NH4Ac, pH 7.0). 
 
a) Relative error (Er) was calculated in ppm as: |Mr exp – Mr theo|/Mr theo × 10
6 (exp = experimental and theo = theoretical). 





 A) Healthy control B) FAP-I patient 
N 




Deconvoluted Average Mr %Ab) 
(%RSD)  
Deconvoluted Average Mr %Ab) 
(%RSD)  Experimental Era) (ppm) Experimental Era) (ppm) 
1. TTR-Cys 13880.4022 13880.9511 40 100 (3.2) 13881.1016 50 100 (4.0) 
2. Free-TTR 13761.2640 13761.9247 48 64 (2.5) 13761.7566 36 61 (3.2) 
3. TTR-Phosphorylated 13841.2439 
13841.7207 
34 
69 (1.3) 13841.0863 
22 
67 (2.8) 
 or TTR-Sulfonated 13841.3283 28 24 




 or TTR-Dehydroxylated           
or TTR-Sulfinic 
13793.2628 13793.9606 51 51 (3.9) 30 
5.  (10) C-G  13715.1713 13715.4042 17 53 (2.8) 13715.4228 18 47 (4.8) 
9. Mutant TTR-Cys (Met30)  13912.4683 Not detected - - 13912.9765 37 44 (3.8) 
